| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/06/2002 | EP1183333A1 Methods of using rnase p reaction mechanisms of action |
| 03/06/2002 | EP1183330A1 Kv10.1, A NOVEL VOLTAGE-GATED POTASSIUM CHANNEL FROM HUMAN BRAIN |
| 03/06/2002 | EP1183271A1 Polymer conjugates of hedgehog proteins and uses |
| 03/06/2002 | EP1183267A1 Retro-inverso peptides derived from interleukin-6 |
| 03/06/2002 | EP1183266A1 Retro-inverso peptides derived from leukemia inhibitory factor |
| 03/06/2002 | EP1183259A2 Azepinoindole derivatives, the production and use thereof |
| 03/06/2002 | EP1183257A1 Triazolopyrimidinol compounds and salts thereof |
| 03/06/2002 | EP1183256A1 Purine derivatives, preparation method and pharmaceutical compositions containing same |
| 03/06/2002 | EP1183252A1 New pharmaceutically active compounds |
| 03/06/2002 | EP1183245A1 Selective npy (y5) antagonists |
| 03/06/2002 | EP1183243A1 Short-acting benzodiazepines |
| 03/06/2002 | EP1183241A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 03/06/2002 | EP1183240A1 Beta2-adrenoceptor agonists |
| 03/06/2002 | EP1183239A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/06/2002 | EP1183237A1 Novel antioxidants, preparation methods and uses |
| 03/06/2002 | EP1183236A1 Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |
| 03/06/2002 | EP1183232A2 Monofluoroalkyl derivatives |
| 03/06/2002 | EP1183042A2 Methods for treating diabetes |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183039A1 Pharmaceutical preparations of bioactive substances extracted from natural sources |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183035A1 Bone marrow transplantation for treatment of stroke |
| 03/06/2002 | EP1183030A1 Methods of making and using n-desmethylzopiclone |
| 03/06/2002 | EP1183029A2 Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction |
| 03/06/2002 | EP1183027A1 Pharmaceutical formulations and methods comprising intranasal morphine |
| 03/06/2002 | EP1183025A2 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
| 03/06/2002 | EP1183024A1 Therapeutic use of melatonin |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | EP1183015A1 Multilayered tablet for administration of a fixed combination of tramadol and diclofenac |
| 03/06/2002 | EP1183014A1 Controlled release and taste masking oral pharmaceutical compositions |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP0994865B1 Triazole compounds and the use thereof as dopamine-d 3-ligands |
| 03/06/2002 | EP0937043B1 Novel substituted tetrahydropyridin derivatives, method of preparation and pharmaceutical compositions containing them |
| 03/06/2002 | EP0876372B1 Heteroarylcarboxamide derivatives |
| 03/06/2002 | EP0760818B1 Use of tetrahydropteridine derivatives as no-synthase inhibitors |
| 03/06/2002 | EP0743945B1 Heterocyclic compounds and their preparation and use |
| 03/06/2002 | EP0740657B1 4-arylisoindole analgesics |
| 03/06/2002 | CN1339068A Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane |
| 03/06/2002 | CN1339066A Alzheimer's disease secretase |
| 03/06/2002 | CN1339028A Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases |
| 03/06/2002 | CN1338942A Self-emulsifying compositions for drugs poorly soluble in water |
| 03/06/2002 | CN1338937A Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 03/06/2002 | CN1338931A Use of anticonvulsant derivatives for treating bulimia nervosa |
| 03/06/2002 | CN1338929A Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1338289A Sobering-up diuranthera tea |
| 03/06/2002 | CN1338281A Prescriptions of 10 moxibustion medicines (for dermatopathy, venereal disease, sore and ilcer) |
| 03/06/2002 | CN1338280A Prescriptions of 12 moxibustion medicine (for beautifying face and hair and treating dermatopathy) |
| 03/06/2002 | CN1338276A Medicine for treating cardiovascular and cerebrovascular diseases and diseases in nerve network system |
| 03/06/2002 | CN1338255A Oily gammariza injection |
| 03/06/2002 | CN1080261C 3-substituted 1-arylindole compounds |
| 03/06/2002 | CN1080260C Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors |
| 03/06/2002 | CA2356797A1 Combination treatment for depression and anxiety |
| 03/06/2002 | CA2356545A1 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/05/2002 | US6353105 Inhibitors of 5-hydroxy-tryptamine reuptake of a monoamine transporter; analogs of cocaine; |
| 03/05/2002 | US6353103 Stress related disorders such as post traumatic stress disorder (ptsd) as well as depression, headache and anxiety. |
| 03/05/2002 | US6353092 Patched-2 polypeptide |
| 03/05/2002 | US6353025 Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same |
| 03/05/2002 | US6353018 Compounds, their preparation and use |
| 03/05/2002 | US6353010 Enzyme inhibitors tumor necrosis factor and phosphodiesterase for antiinflammatory agents |
| 03/05/2002 | US6353008 Serotonin reuptake inhibitor as antidepressants |
| 03/05/2002 | US6353002 Therapeutic agents |
| 03/05/2002 | US6352999 Drugs for nervous system disorders, parkinson's disease and antidepressants |
| 03/05/2002 | US6352995 Spiro-quinuclidine derivatives, their preparation and use |
| 03/05/2002 | US6352994 Nervous system disorders; psychological disorders |
| 03/05/2002 | US6352990 CRF receptor antagonists and methods relating thereto |
| 03/05/2002 | US6352988 High affinity for d4 receptors; treatment of schizophrenia, other psychoses, anxiety disorders, depression, alcohol abuse, impulse control disorders, aggression |
| 03/05/2002 | US6352986 Treatments for nervous disorders |
| 03/05/2002 | US6352984 For treatment of psychological disorders, schizophrenia |
| 03/05/2002 | US6352981 Treat disorders which respond to dopamine d.sub.3 ligands such as schistosomiasis, schizophrenia, depression, neuroses or psychoses |
| 03/05/2002 | CA2266565C Azabicyclic rotomase inhibitors |
| 03/05/2002 | CA2206122C Arylacrylamide derivatives |
| 03/05/2002 | CA2049850C 4-substituted dihydropyrido[4,3-d]pyrimidines as analgesics and topical antiinflammatory agents for the treatment of skin disorders |
| 02/28/2002 | WO2002017358A2 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists) |
| 02/28/2002 | WO2002016620A2 Modulation of stem cell differentiation |
| 02/28/2002 | WO2002016615A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 02/28/2002 | WO2002016597A2 Lipid metabolism enzymes |
| 02/28/2002 | WO2002016587A2 Microtubule-associated proteins and tubulins |
| 02/28/2002 | WO2002016585A2 Imidazoline receptor homologs |
| 02/28/2002 | WO2002016584A2 Process for the preparation of neutrophil inhibitory factor |
| 02/28/2002 | WO2002016436A2 ANTIBODIES TO HUMAN IL-1$g(b) |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016430A2 Peptide with effects on cerebral health |
| 02/28/2002 | WO2002016417A2 Transgenic animal model for neurodegerative disease and uses thereof |
| 02/28/2002 | WO2002016408A2 Gpe analogs |
| 02/28/2002 | WO2002016395A1 Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016381A2 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016365A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity |
| 02/28/2002 | WO2002016363A1 Imidazolophthalazine derivatives as ligands for gabaa receptors |
| 02/28/2002 | WO2002016359A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | WO2002016358A2 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 02/28/2002 | WO2002016357A2 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 02/28/2002 | WO2002016356A2 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) |
| 02/28/2002 | WO2002016355A2 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |